Sign in

CIK 0001626971

  • Non-accelerated filer
  • Smaller reporting company

Corvus Pharmaceuticals, Inc.

Sign in to watch
Ticker
CRVS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464670809
Phone
+1 650-900-4520
Business address
901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Open-market buy Director bought 4,716 shares at $13.09 ($61,732)
  2. 4 Open-market buy Director bought 6,800 shares at an average $11.77 ($80,035)
  3. 4 Open-market buy Director bought 6,800 shares at an average $11.77 ($80,035)
  4. 4 Open-market buy President and CEO bought 30,300 shares at an average $10.00 ($302,981)
  5. 4 Open-market buy 10% owner bought 70,000 shares at $10.00 ($700,000)
  6. 4 Open-market buy 10% owner bought 666,666 shares at $15.00 ($9,999,990)
  7. 4 Open-market buy Director bought 550,000 shares at $15.00 ($8,250,000)
  8. 4 Open-market buy Director bought 550,000 shares at $15.00 ($8,250,000)
  9. 4 Open-market buy 10% owner bought 200,000 shares at $15.00 ($3,000,000)
  10. 4 Conversion President and CEO acquired 328,765 shares (conversion)
  11. 4 Conversion Chief Financial Officer acquired 42,608 shares (conversion)
  12. 4 Open-market buy Director bought 200,000 shares at $15.00 ($3,000,000)
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 4 Derivatives Options or other derivatives
  17. 4 Derivatives Options or other derivatives
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 12 of 13 · 252 filings